Prognostic Value of the Haemoglobin–Albumin–Lymphocyte–Platelet Score in Head and Neck Cancer: A Systematic Review and Meta‐Analysis
Clinical Otolaryngology · 2026-09 · 51 (5) · 635-643
DOI: 10.1111/coa.70134 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Otolaryngology, online erschienen am 21.06.2026. Verfasst von Yu Hsin Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Hemoglobins, Serum Albumin. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
The haemoglobin–albumin–lymphocyte–platelet (HALP) score is an inflammation‐ and nutrition‐related biomarker derived from routine blood tests, but its prognostic value in head and neck cancer (HNC) has not been quantitatively synthesized. This systematic review and meta‐analysis aimed to evaluate the association between pretreatment HALP and survival outcomes in HNC.
Methods
PubMed, Embase and Web of Science were searched to 24 January 2026 for cohort studies reporting hazard ratios (HRs) for survival outcomes by pretreatment HALP in HNC. Reviews, case reports, conference abstracts without full text, and studies lacking survival data were excluded. Random‐effects meta‐analysis was performed and risk of bias was assessed using QUIPS. The review was prospectively registered in the Open Science Framework.
Results
Six retrospective cohort studies (1759 patients) were included. Higher pretreatment HALP was associated with improved overall survival (pooled HR 0.52, 95% CI 0.41–0.67; I 2 = 17.6%) and disease‐free survival (pooled HR 0.60, 95% CI 0.47–0.76; I 2 = 0.0%). After excluding the metastatic cohort, the pooled overall survival estimate remained similar (HR 0.56, 95% CI 0.45–0.70; I 2 = 0.0%), and leave‐one‐out analyses showed stable estimates (HR range 0.48–0.56).
Conclusions
Higher pretreatment HALP is associated with favourable survival in HNC. However, reported cutoff values for HALP have been inconsistent across studies. HALP might be helpful for clinicians in evaluating the prognosis of HNC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
- Head and Neck Cancer Surveillance and Research Group, Far Eastern Memorial Hospital, New Taipei, Taiwan.
- Department of Nursing, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
- Master Program of Big Data in Medical Healthcare Industry, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
- Department of Otolaryngology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
- Department of Electrical Engineering, Yuan Ze University, Taoyuan, Taiwan.
ORCID-Profile: Li-Jen Liao
Zitieren
APA
Lin, Y. H., Huang, H. Y., Hsu, W. L., & Liao, L. J. (2026). Prognostic Value of the Haemoglobin–Albumin–Lymphocyte–Platelet Score in Head and Neck Cancer: A Systematic Review and Meta‐Analysis. Clinical Otolaryngology, 51(5), 635-643. https://doi.org/10.1111/coa.70134
Vancouver
Lin YH, Huang HY, Hsu WL, Liao LJ. Prognostic Value of the Haemoglobin–Albumin–Lymphocyte–Platelet Score in Head and Neck Cancer: A Systematic Review and Meta‐Analysis. Clinical Otolaryngology. 2026;51(5):635-643. doi:10.1111/coa.70134
BibTeX
@article{Lin2026,
author = {Lin, Yu Hsin and Huang, Hsin Yi and Hsu, Wan-Lun and Liao, Li-Jen},
title = {Prognostic Value of the Haemoglobin–Albumin–Lymphocyte–Platelet Score in Head and Neck Cancer: A Systematic Review and Meta‐Analysis},
journal = {Clinical Otolaryngology},
year = {2026},
volume = {51},
number = {5},
pages = {635--643},
doi = {10.1111/coa.70134}
}
EUVIMED